ABSI
NASDAQAbsci Corporation
News · 26 weeks46+200%
2026-04-192026-10-11
Mix1490d
- Insider6(43%)
- Other4(29%)
- Earnings2(14%)
- SEC Filings2(14%)
Latest news
25 items- INSIDERSEC Form 4 filed by Absci Corporation4 - Absci Corp (0001672688) (Issuer)
- INSIDERSEC Form 4 filed by Absci Corporation4 - Absci Corp (0001672688) (Issuer)
- INSIDERSEC Form 4 filed by Absci Corporation4 - Absci Corp (0001672688) (Issuer)
- PRAI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Bost
- PRAbsci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com.
- PRAbsci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for EndometriosisPhase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis. The planned Phas
- INSIDERCFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)4 - Absci Corp (0001672688) (Issuer)
- PRAbsci to Participate in Upcoming Investor ConferencesVANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference (New York, NY) Fireside chat on Tuesday, September 15th at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) Fireside chat on Wednesday, September 16th at 7:45 a.m. Eastern Time / 4:45 a.m. Pacific Time Interested parties may access live and archived webcasts o
- PRMost AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c
- SECSEC Form 10-Q filed by Absci Corporation10-Q - Absci Corp (0001672688) (Filer)
- SECAbsci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
- PRAbsci Reports Business Updates and Second Quarter 2026 Financial and Operating ResultsAnnounced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026. "The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sh
- INSIDERSEC Form 4 filed by CMO, Head of R&D Somaratne Ransi Mudalinayake4 - Absci Corp (0001672688) (Issuer)
- INSIDERSEC Form 3 filed by new insider Somaratne Ransi Mudalinayake3 - Absci Corp (0001672688) (Issuer)
- PRAs AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H
- PRAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. T
- INSIDERDirector Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)4 - Absci Corp (0001672688) (Issuer)
- PRThe Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in ParallelA wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /CNW/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the
- INSIDERChief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)4 - Absci Corp (0001672688) (Issuer)
- SECSEC Form 8-K filed by Absci Corporation8-K - Absci Corp (0001672688) (Filer)
- SECSEC Form 424B5 filed by Absci Corporation424B5 - Absci Corp (0001672688) (Filer)
- PRAbsci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial InvestorsEli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions. The gross proceeds from the offering, bef
- SECAbsci Corporation filed SEC Form 8-K: Financial Statements and Exhibits8-K - Absci Corp (0001672688) (Filer)
- PRAbsci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027 VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with
- PRThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItIssued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
ABSI FAQ
7 questionsWhat does Absci Corporation do?
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.Where does ABSI stock trade?
Absci Corporation (ABSI) is listed on NASDAQ.What sector and industry is ABSI in?
Absci Corporation operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Absci Corporation go public?
Absci Corporation (ABSI) completed its IPO in 2021.What are analysts saying about ABSI?
Absci Corporation has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $1200.00 price target on 2026-06-04. Recent price targets range from $432.00 to $1200.00.What companies are similar to ABSI?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), MEDP (Medpace Holdings Inc.), PPD (PPD, Inc.), CRL (Charles River Laboratories International Inc.). Compare ABSI side-by-side with any of them on Quantisnow.How can I track ABSI on Quantisnow?
Quantisnow aggregates Absci Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABSI to receive live email and push alerts on every new disclosure.